Reintroduce Yourself to the Power of the GS FLX+ System
What could you do with 1,000 bp reads? How about a million of them?
- Uncover the hidden biology in previously difficult-to-sequence regions of genomes, transcriptomes, and metagenomes
- Discover novel complex genetic variants, including large insertions, deletions and block substitutions
- Coming Soon! Long amplicon sequencing of 700-800 bp reads for targeted sequencing and 16S/18S metagenomics studies. Download AGBT Poster: Long Amplicon Sequencing on GS FLX+ System
Table 1. Example Base Contribution Profile from a GS FLX+ System Run using software v2.8 (human DNA sample). Plot shows the number of bases contributed by reads of a specific length. The blue shading represents 50% of total bases, i.e. the bases contributed by reads of the N50 length or longer. Actual results depend on specific sample and genome characteristics.
What's New with GS FLX+ Software v2.8?
- Improved long read sequencing performance.
- Simple sample de-multiplexing and improved SNP detection with GS Reference Mapper.
- Automatic detection of single base insertions and deletions, and easy amplicon analysis setup with new Project Blueprints in GS Amplicon Variant Analyzer.
GS FLX+ long amplicons
Drive your targeted sequencing and 16S/18S rRNA metagenomics studies to new lengths!
|Read Length||Up to 1,000 bp||Up to 600 bp|
|Mode Read Length||700 bp||450 bp|
|Throughput||700 Mb||450 Mb|
|Reads per Run||~1,000,000|
|Run Time||23 hours||10 hours|
Table 1. Performance of the GS FLX+ System with Sequencing Kit XL+ and Sequencint Kit XLR70. Actual results depend on specific sample and genomic characteristics. *Consensus accuracy at 15x coverage E. coli.
See What Others Are Saying
We have experienced excellent results in our laboratory using the latest GS FLX+ software. All sequencing metrics, including read length, have exceeded our expectations. We are excited to use the platform in wheat transcriptome studies, where the long reads are critical for full-length de novo assembly of cDNA transcripts and splice variant investigation.
- Hiroshi Tarui, RIKEN Omics Science Center and a collaborator KIHARA Institute for Biological Research, Yokohama City University, Japan
The performance of the GS FLX+ System has continuously improved since upgrading to software v2.8. In general, on our first few sequencing runs with the improvements, we achieved 200 bp longer reads, 20% higher passed filter rates, and 20% increase in total bases. We are eager to raise awareness of these improvements to our clients, emphasizing the uniqueness of the 454 extra-long reads and high quality in comparison to other next generation sequencing platforms.
- HyungTae Kim, CEO, Macrogen, Korea
We have had a very good experience with the latest improvements to the GS FLX+ System. Compared to the first release of the upgrade over a year ago, we are seeing a higher percentage of good reads and the read length appears to be much longer. In addition, the variability in the performance between runs observed previously has vanished with the new improvements. We are eager to use the GS FLX+ System in our de novo genome assembly and metagenomics projects.
- Petri Auvinen and Lars Paulin, University of Helsinki, Finland
We are extremely pleased with the latest improvements to the GS FLX+ System. We are consistently getting higher overall sequencing performance and longer read lengths than before the new software update. As a service provider, this improved performance is critical for us to successfully serve our customers in their various shotgun sequencing projects.
- Shaukat Rangwala, Senior Vice President, MOgene
Our experience with the latest GS FLX+ hardware and software improvements has been very positive. We are seeing a marked increase in read length and overall system performance. We are excited to apply the GS FLX+ data to our metagenomics projects, where the longer reads resulted in a higher information content thus enabled a more meaningful bioinformatic interpretation. We hope to further optimize and expand our use of the platform in this application field in the future.
- Dr. Ralph Oehlmann, Director Business Development, IMGM Laboratories GmbH, Martinsried, Germany